Investors need to be careful about which pharmaceutical stocks they own.
News & Analysis: Allergan
The drugmaker's Q2 revenue and earnings beats enable it to raise full-year guidance.
You might think it's too late to profit with this soon-to-be-acquired drug stock. Think again.
Is AbbVie's stock a bargain now that it's tying up with Botox maker Allergan?
AbbVie's buying Allergan for around $63 billion, and shareholders from both companies are not on board.
AbbVie became the latest player to pursue a pharma megadeal, and Lennar beat expectations for the second quarter.
Investors are cheering Allergan and jeering AbbVie after the announcement of a major acquisition.
Overpaying for Allergan would be a serious misstep.
Here's why the drugmaker topped revenue and earnings expectations in Q1.
AGN earnings call for the period ending May 7, 2019.